These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 38188524)

  • 1. Voluntary wheel running improves molecular and functional deficits in a murine model of facioscapulohumeral muscular dystrophy.
    Bittel AJ; Bittel DC; Gordish-Dressman H; Chen YW
    iScience; 2024 Jan; 27(1):108632. PubMed ID: 38188524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular and Phenotypic Changes in FLExDUX4 Mice.
    Murphy K; Zhang A; Bittel AJ; Chen YW
    J Pers Med; 2023 Jun; 13(7):. PubMed ID: 37511653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy.
    Bouwman LF; den Hamer B; van den Heuvel A; Franken M; Jackson M; Dwyer CA; Tapscott SJ; Rigo F; van der Maarel SM; de Greef JC
    Mol Ther Nucleic Acids; 2021 Dec; 26():813-827. PubMed ID: 34729250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Molecular and Histopathology in Diaphragm Muscle of the Double Transgenic ACTA1-MCM/FLExDUX4 Mouse Model of FSHD with Systemic Antisense Therapy.
    Lu-Nguyen N; Malerba A; Antoni Pineda M; Dickson G; Popplewell L
    Hum Gene Ther; 2022 Sep; 33(17-18):923-935. PubMed ID: 35078334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
    Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
    Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy.
    Bittel AJ; Sreetama SC; Bittel DC; Horn A; Novak JS; Yokota T; Zhang A; Maruyama R; Rowel Q Lim K; Jaiswal JK; Chen YW
    Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32759720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic exercise mitigates disease mechanisms and improves muscle function in myotonic dystrophy type 1 mice.
    Manta A; Stouth DW; Xhuti D; Chi L; Rebalka IA; Kalmar JM; Hawke TJ; Ljubicic V
    J Physiol; 2019 Mar; 597(5):1361-1381. PubMed ID: 30628727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target.
    Heher P; Ganassi M; Weidinger A; Engquist EN; Pruller J; Nguyen TH; Tassin A; Declèves AE; Mamchaoui K; Banerji CRS; Grillari J; Kozlov AV; Zammit PS
    Redox Biol; 2022 May; 51():102251. PubMed ID: 35248827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systemically Administered Unconjugated Antisense Oligonucleotide Targeting DUX4 Improves Muscular Injury and Motor Function in FSHD Model Mice.
    Kakimoto T; Ogasawara A; Ishikawa K; Kurita T; Yoshida K; Harada S; Nonaka T; Inoue Y; Uchida K; Tateoka T; Ohta T; Kumagai S; Sasaki T; Aihara H
    Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase A activation inhibits
    Cruz JM; Hupper N; Wilson LS; Concannon JB; Wang Y; Oberhauser B; Patora-Komisarska K; Zhang Y; Glass DJ; Trendelenburg AU; Clarke BA
    J Biol Chem; 2018 Jul; 293(30):11837-11849. PubMed ID: 29899111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
    Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
    Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p38
    Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
    J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Systemic Treatment of a Mouse Model Displaying Chronic FSHD-like Pathology with Antisense Therapeutics That Inhibit
    Lu-Nguyen N; Dickson G; Malerba A; Popplewell L
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
    Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
    Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
    Jagannathan S
    Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction.
    Turki A; Hayot M; Carnac G; Pillard F; Passerieux E; Bommart S; Raynaud de Mauverger E; Hugon G; Pincemail J; Pietri S; Lambert K; Belayew A; Vassetzky Y; Juntas Morales R; Mercier J; Laoudj-Chenivesse D
    Free Radic Biol Med; 2012 Sep; 53(5):1068-79. PubMed ID: 22796148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.
    Schätzl T; Kaiser L; Deigner HP
    Orphanet J Rare Dis; 2021 Mar; 16(1):129. PubMed ID: 33712050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.